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Intervertebral disc (IVD) disease is a disease common to dogs, especially chondrodystrophic dogs (dogs with short legs compared to their body height). In IVD disease the tissues of the intervertebral disc are degenerating which leads to loss of function and degeneration. 
To find a cure for the disease this study focuses on the molecular pathways playing an important role in IVD disease, which is done by determining a set of 15 reference genes which can be used in further studies.
These reference genes will be assessed by using the quantitative PCR (qPCR) method with a SYBRgreen dye.
A total of 42 samples were used from dogs of different breed and disease state (diseased/healthy), from which 39 samples remained for analysis.
The qPCR data were analysed using the software programs geNorm and NormFinder.
Results from the analysis showed that the combination of RPS19, SPRP, HPRT and YWHAZ would be the best choice when looking at the whole IVD.

Introduction
Intervertebral disc (IVD) disease is a common disease in dogs. Occurring mostly at later age, but in certain breeds also at a much younger age (chondrodystrophic dogs), it can give rise to clinical symptoms such as back- or neck pain, urine and fecal incontinence, hyperesthesia and even paresis, paralysis or other neurological disorders.(1-3)
Clinical manifestations of IVD-related disease include cervical spondylomyelopathy, thoracolumbar disc disease and degenerative lumbosacral stenosis. These diseases are highly associated with degeneration of the IVD. The IVD is localized between the individual vertebrae and acts as a cushion to absorb the forces on the spinal column.
The intervertebral disc consists of three different tissues (See Fig.1).
The nucleus pulposus (NP), this is a gelatinous mass which is rich in water attracting proteoglycans, chondrocytes and collagen. The NP lies just in between the adjacent vertebrae.
The annulus fibrosus (AF) encapsulates the NP and consists of almost merely collagen, which lies in multiple layers over each other, each layer having its fibres orientated in an other direction. This gives the AF a great strength in keeping the NP in place, within the AF.
The fibrocartilaginous endplates are situated just at the surface of the vertebrae and mark the transition of vertebra to intervertebral disc, the endplate is responsible for the transport of nutrients and waste in and out of the intervertebral disc since there is no blood-circulation in the intervertebral disc.
 In the healthy state the NP consists of approximately 80% water, which is attracted to the disc through negatively charged proteoglycans embedded in a collagen rich network.
In a dog with IVD disease the ratio between proteoglycans and collagen is altered in favour of the collagen. Due to the loss of proteoglycans the IVD loses its water content and the ability to attract water. By losing these abilities, the IVD loses its specific structure and functionality.(1, 4)
Hansen developed a classification in IVD degeneration on anatomic-pathologic changes. Using this classification IVD degeneration can be crudely divided in two different groups.

The first group exclusively involves chondrodystrophic dogs, this are dogs with abnormal short legs compared to their body height, such as dashhunds, beagles and basset hounds. IVD degeneration in chondrodystrophic dogs occurs at a much greater scale, prevalence of IVD degeneration in chondrodystrophic dogs is much higher and most of the time multiple IVD’s are affected. Degeneration of the IVD in chondrodystrophic dogs occurs much more rapidly and thereby seems to be an accelerated version of IVD degeneration in normal (non-chondrodystrophic) dogs. This is why these dogs can show clinical signs at a much younger age (as young as 2 years old). This form of IVD is suspected to have a hereditary aspect which all chondrodystophic dogs share.
The second type of degeneration, called IVD degeneration type-2, is mainly seen in non-chondrodystrophic dogs, these are dogs with legs proportional to the body height. IVD degeneration in this group occurs at older age (over 8 years) and mostly affects only one IVD. The changes in these IVD’s are progressing slowly and therefore clinical signs occur at an older age (if shown at al). This form of IVD degeneration possibly occurs due to the constant wear and tear of the IVD through the years because of the forces and load pressing on it.(1, 4) 
Cervical spondylomyelopathy (CSM) (or wobbler syndrome)(3), degenerative lumbosacral stenosis (DLS)(2) and thoracolumbar disc disease (TDD)(1) are all diseases which have their origin in IVD degeneration or are very similar to IVD degeneration. They represent the different locations in the spine where degeneration of the intervertebral disc can occur. DLS affects the lumbosacral region of the spinal column, TDD affects the thoracolumbar IVD’s and CSM affects the cervical IVD’s.
Current therapies for IVD related disease are based on conservative treatment or are highly invasive, most of them will only temporarily ease the suffering.(1) New therapies which are aimed at the regeneration of the intervertebral disc, such as cell based therapy, gene therapy and the administration of anabolic growth factors, are still in development and not yet ready for use. 
Cell based therapies are based on injecting the intervertebral disc with healthy cells, mostly cultured from the patient itself, which should restore the cell population and the extracellular matrix and thereby restoring the functionality of the IVD. Currently in vivo research has been done on small animals.(5)
With gene therapy, expression of certain proteins is stimulated or inhibited that have an important role in the regeneration en degeneration of the IVD. Current studies on gene therapy for IVD disease are still focused at small animal models.(6, 7)
The use of anabolic growth factors for the regeneration of the IVD should stimulate autonomous cells to proliferate again and produces more matrix to restore the decreasing amount of cells and matrix. Multiple growth factors are being researched, but most of the most advanced research is still using small animal models and it is still unsure which growth factors work best.(8, 9)
Sadly not much is known yet about the pathology of IVD disease, which molecular pathways are involved is still for the most part unclear. 
By discovering which bio-molecular pathways are involved in the process of IVD degeneration, therapies might be developed that can positively influence anabolic pathways and decelerate IVD degeneration or even restore functionality of the IVD. Currently, those bio-molecular studies that study these pathways are becoming more and more popular. One of the techniques used in these studies is measuring the gene expression levels.
At the moment Quantitative Polymerase Chain Reaction (qPCR) is a method that is becoming more popular for measuring gene expression.(10)
QPCR works just like a normal PCR: DNA is duplicated during cycles by the DNA-polymerase enzyme, by using primers specific to the gene this gene can be targeted, replicating only the cDNA of the targeted gene. But in contrary to a normal PCR, the product isn’t measured after the PCR is completed but during the PCR. By adding a fluorescent dye in the master mix, that will bind to double stranded DNA, the intensity of the fluorescent light can be measured and be used to determine the amount of DNA that is created. By measuring the increase in intensity during the run (or real-time) it can be calculated how much DNA is created (the more DNA is created the brighter the fluorescent signal will get), which can give an insight in with how much DNA the reaction was started.
Advantages of qPCR are its high sensitivity and thus its low sample usage, its ease to use and the fact that it can be used on a rather large scale making it much more cost and time efficient than previous methods such as northern blot analysis, ribonuclease protection assay and competitive RT-PCR.(10-15)
Due to its high sensitivity it can detect minute concentrations of RNA, which also makes it sensitive to errors and deviations in researcher, sample or equipment. Therefore essential control steps must be installed to prevent these errors and deviations from disrupting the data.(10)
One of these steps is the use of stable reference genes to be used as a intergroup or inter-sample standard to which the gene expression can be measured for a relative quantification. These reference genes represent a standard expression, which should be the same in every individual and under any relevant condition, to which the expression level of genes of interest can be normalised.(10, 13, 16)
Although data might differ between scientist, the data of different genes between groups and samples from a single scientist will all contain the same error and so this stable standard line can be used to quantify and make the results comparable between researches.
These type of analysis has already been described in multiple species (eg. human(16), pig(12), cat(17), dog(15)) and tissues (eg. skin(14), liver, mammary gland, heart(15) and articular tissues(11)). The application of such a method should also be appropriate for research on IVD degeneration in dogs.
The goal of this research is to evaluate 15 potential stable reference genes, this being beta-2-microglobulin (B2MG), β-actine (Actb), hypoxanthine guanine phosphoribosyl transferase (HPRT), ribosomal protein L13 (RPL13), Glyceraldehyde 3 phosphate dehydrogenase 1 (GAPDH), signal recognition particle receptor (SRPR), heterogeneous nuclear ribonucleoprotein H1 (hnRNPH), glucuronidase beta (GUSB), ribosomal protein L8 (RPL8), ribosomal protein S5 (RPS5), ribosomal protein S19 (RPS19), hydroxymethylbilane synthase (HMBS), TATA box binding protein (TBP), succinate dehydrogenase complex subunit A (SDHA) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ). Gene expression will be measured to determine which genes are most stably expressed in a variety of  IVD tissue, this being the AF and the NP, selected from dogs of different breeds, ages, and stage of degeneration and how many genes are needed for a usable standard for further gene expression research to determine the genes responsible for IVD degeneration in dogs.
Samples used from dogs are partially tissue samples and partially already isolated RNA samples. All dog samples come from dogs of varying age, breed and disease state (healthy versus degenerated, following the Thompson grading).
Materials and methods
Sample collection
Animals used for collection were euthanized in other unrelated projects. Collection of the material was done by first cutting the vertebra in to single units from which one half of the NP and AF were collected, snap frozen in liquid nitrogen and stored at -70°C.
All methods were approved by the responsible ethical committee as required under Dutch legislation.

RNA isolation
Samples were kept at liquid nitrogen until homogenisation. For homogenisation an Euroturrax T20 standard (IKA Labortechnik) was used. Further procedures were done following the Protocol: Purification of Total RNA using the RNeasy Fibrous tissue Mini Kit and with the Fibrous tissue MiniKit (Qiagen). A DNase-1 digestion step was preformed on-column as described in the protocol. For eluation 32 ul RNase-free water from the kit was used. After centrifugation the eluate was used to wash the column again for higher RNA concentrations.
Centrifugation was performed with an Eppendorf centrifuge S415 R and eventually, the quantity was determined measuring the concentration of the isolated RNA with the NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies).
After isolation samples were stored at -70°C until cDNA synthesis.

cDNA synthesis
For cDNA synthesis, the RNA that would be needed for the RT reaction was calculated to 20ng per sample so that every cDNA sample would contain more or less the same concentration after the RT reaction was completed 
the RNA samples were retrieved from the -70oC and were left to thaw. After thawing, the samples were mixed and centrifuged.
After this step the cDNA synthesis was performed using the primers from fig.2 (which were a mix of oligo-dt and hexamer primers) and the iScript™cDNA Synthesis Kit (Bio-Rad) following the protocol from the same kit. Preparation of the strips was done in a UV-cabinet to minimize contamination.
The actual RT-PCR cycle was preformed in a MJ thermal cycler (Bio-Rad).
After synthesis, the cDNA was stored at -20oC, until further use.

qPCR
Samples can be grouped by tissue type: Nucleus pulposus or Annulus fibrosus; Dog breed: X-breeds, Labrador (Non-chondrodystrophic breeds) or Beagle (chondrodystrophic breed) and the group: “All”, containing all the samples.
For qPCR the cDNA sample were retrieved from -20oC and all samples were filled out in PCR-strips en diluted in the proper concentrations. This would keep manipulation to a minimum and would greatly decrease preparation time for the qPCR reaction. Since the samples were used in a short period afterwards (the next week) there were no issues with conservation or loss of quality. The filled out strips were again stored at -20oC.
For the qPCR reaction the primers shown in  fig.2 were used. A SYBRgreen dye was used, using the iQ™ SYBR® Green Supermix 170-8882 kit (Bio-Rad). The protocol included in this kit was used for setting up the qPCR plates.
A standard line of 5 wells was created with a dilution step of 4x and a no template control was added for the qPCR reaction, this was done so that all the 42 sample would fit on one plate so no inter-run errors would occur for the individual genes.
The qPCR reaction was performed in the iCylcer iQ™ (Bio-Rad) fitted with a MyiQ™ Single-Color Real-Time PCR Detection System (Bio-Rad).
The centrifuge steps of the vials, PCR-strips and -plates were done with respectively an Eppendorf MiniSpin, an Eppendorf centrifuge 5804 and an Eppendorf centrifuge 5417 C.
Analysis of data
The analysis of the data is performed using the much used the computer software programs geNorm™, using the geNorm applet of the statistics program R (version 2.12.0, R development Core Team) (13), and NormFinder.
GeNorm™ works through calculating the expression stability for each individual reference gene as the pairwise variation for that gene with all other tested genes.
By subsequently excluding the gene with the lowest expression stability a ranking can be made for the most stable genes. The M value given for every gene is the arrhythmic mean of all pairwise variations of the given gene. The pairwise variation, calculated by geNorm, gives an insight in minimum amount of reference genes that are to be used to get a trustworthy internal standard.
GeNorm™ also calculates what the optimal number of reference genes needed is for the best normalisation. This is done by comparing the pairwise variation of the best series of genes and that series of genes plus the following most stable gene.(13)
NormFinder uses a model based approach, in which it calculates the inter- and intra-group variation. These inter- and intra-group variations are then used to calculate a stability value for each gene. The gene with the lowest stability values is marked as the most stable.
Both methods are used to analyse the data, although, since the geNorm applet of R has the option to differ between groups, the accent lies on geNorm.

Results
Three of the 42 samples had to be excluded from the study since no Cq values were measured during the qPCR run of one of the genes.



















When looking at the M values, on which the gene ranking is based, in the “All” group all genes had an M value below the M=1.5. Overall can be seen that B2M is the most unstable gene in all groups, having a rank of 13 or 14. Although standing at rank 1 of the “All” group RPS5 does not seem as stable when looking at other groups where it has a rank of between 1 and 10. RPS19, SPRP and RPL13 seem to have a great intergroup stability, ranking in all groups between the 1 and 3 (Fig.4).
To accomplish a pairwise variance of 0.15 (advised by geNorm as a maximum threshold) in the “All” group a minimum of 4 reference genes was needed, the pairwise variance between the V4/5 was below the 0.15 threshold meaning that including a fifth gene was not needed to achieve a internal standard that is stable enough. 
In the other groups was seen that the usage of 2 or 3 genes were enough to get a trustworthy internal standard (Fig.5).

Although some difference are seen in the ranking between geNorm and NormFinder, NormFinder also recognises RPS19, RPL19 and SPRP as three of the more stable genes.


























It is interesting to see the large similarity in gene ranking between geNorm and NormFinder, although it is uncertain why there are a few big differences, such as RPS5 in the “All” group. This difference might be explained due to the fact that RPS5 belongs to the same group of genes as RPS19 and RPL13 which score high with both geNorm and NormFinder. Since geNorm compares genes to calculate stability values geNorm would rank it as stable while NormFinder would not because it does not compare genes.
The difference in the number of genes needed between groups seen in fig.5 is also worth noticing. Especially worth noticing is the difference between the “AF” group and the other tissue and breed groups. The “AF” group spikes in the v2/3 and the v3/4, which would explain the same spike seen in the “All” group. An explanation for this spike in the “AF” group might be that parts of the endplate (which is rich in a lot of other cell types) was included is some of the samples, resulting in more genes needed for a trustworthy standard.









NormFinder  agrees with most of these findings, keeping the minor variations in mind and two major variations (this being PRS5 and GAPDH). Also NormFinder showed that the combination of HMBS and RPL13 should be used for the internal standard, NormFinder makes no conclusions on the number of genes that should be used for the internal standard. Since RPL13 also scores high in geNorm it is included in the list for the internal standard, HMBS score only intermediate and therefore will not be included.

The risk of using only one reference gene, unfortunately most often applied,  is that the normalisation of the expression of a target gene to only one reference gene give a false expression level. When only a single reference gene is used that shows differing expression levels, which is the case in unstable reference genes, it could still follow a pattern giving it a only seemingly stable appearance but will give false results when used in determining the expression level of the target gene. When using multiple genes the change that such unstable genes will not be detected will be greatly reduces since it is highly unlikely that all the used reference genes show the same unstable pattern.
For example in this study the frequently used beta-actin or GAPDH score very low in expression stability, in geNorm as well as in NormFinder. Even more worrisome is the fact that most gene expression studies in orthopaedics describe the use of only one of these unstable reference genes. By definition, inclusion of only one single reference gene, does not lead to proper standardization since the expression stability of this gene is used to define its own expression stability. This is not just anacademic fine-tuning, proper controls are crucial to obtain relevant data. Inappropriate standardizations may very well lead to wrong conclusions. The cost to include an evaluation of reference gene stability expression in each experiment is just a fraction of the total cost that are usually connected with publication, including experimental animal costs and publication fees. Per additional reference gene, less then three hours of time are needed.

Although the results look promising and usable for further research, there are still some issues that could have improved reliability of the results.
More samples could have been used in the study. In this study 42 RNA samples were selected from a larger database of RNA samples since it was cost efficient and would not need inter-run calibrations. By using more samples inter-run calibrations would have to be included, but would probably have a positive effect on the reliability of the results. A related issue is the number of samples groups and the number of samples within these sample groups. In this study only a difference was made between diseased versus healthy and between breed (mix breed, Labrador, beagle). In addition the age of the dogs could have been grouped to see if this effects the results and diseased IVD’s could have been graded in which stadium of the disease the affected IVD was so this could be grouped too.
The number of samples contained in the groups could also be extended, which would immediately lead to a greater number of samples overall.
No minRT controls were included in the qPCR runs so there was no control on nonspecific gDNA amplification, including this would have given a more reliable view on the qPCR product and readings.
A minimum list of information, described under MIQE precis(18) is needed to allow other researchers to repeat and appreciate the data. This was not strictly followed in this study but will make repeatability and appreciation of the results more easy and more reliable.

With the results from this study further research can be done searching for the genes that play a major role in IVD disease in dogs by using the best genes from this study for the internal standard so a reliable internal standard can be made to asses the expression of suspected genes.
By finding the genes responsible for IVD disease it might be able to find ways to either stimulate or inhibit the expression of those genes. Finding these genes and a way to regulate them could be important for the development of therapies that stop the disease from getting worse in affected patients and, perhaps, even restore disc height and functionality of affected IVD’s.

It can be concluded that, when researching for genes involving in IVD disease, the combination of the four genes: RPS19, SPRP, HPRT and YWHAZ , is the best choice since they show the best overall stability. When regarding the individual tissue types and dog breeds, fig.5 shows which genes are best to use for a reliable internal standard.
An other important conclusion from these analysis is that for each experiment in which reference genes are used, these reference genes must be evaluated on stability and optimal number of genes. Although this message is spreading for about five years, unfortunately, high ranking journals still only accept GAPDH as stable reference gene.
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Fig.1: transverse dissection of the IVD, showing the gelatinous NP in the centre and the fibrous AF surrounding the NP.(2)


























Fig.3: Gene stability calculated using geNorm; there are always two genes at number one since geNorm calculates the expression stability by comparing genes, the best two genes can not be distinguished.

















































Fig.4: Average expression stability (M) and group ranking by geNorm; since the ranks differ from group to group, ranking is included in the figure. The “Labrador” Group represented in purple shows the best results giving the lowest M-values. The “All” group shows the worst results, giving the highest M-values.



